Beyond Brand vs. Generic: What Really Drives Treatment Decisions After Repeated Failures

In this episode, 'Beyond Brand vs. Generic: What Really Drives Treatment Decisions After Repeated Failures,' the panelists explore the following critical questions:

1. How do you weigh the options of choosing a generic vs a branded option for patients who have previously failed treatments? What factors inform your treatment decisions?
2. How much does the "path of least resistance" (i.e., prior authorization burdens, provider coverage, step-therapy requirements) vs. "clinical ideal" factor in your treatment decisions?

The panel examined how the choice between branded and generic medications for treatment-resistant patients is ultimately about identifying the right treatment for the right indication, a principle that requires clinicians to remain current with emerging mechanisms of action and to resist the tendency to default to older agents simply out of habit or comfort. The panelists also challenged the notion of so-called "me too" medications, emphasizing that meaningful differences in efficacy, tolerability, and clinical indication exist across agents within the same class, and that provider education is essential to ensuring patients have access to the full breadth of available options. The discussion further underscored that the long-term costs of repeated treatment failures, including emergency department visits, hospitalizations, and patient demoralization, far outweigh the short-term savings of defaulting to the path of least resistance, making the case that more effective treatments should be considered earlier in the algorithm rather than reserved as last resorts.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'The Ripple Effect of Coverage Delays: Patient Harm and Preventable Crises in Psychiatry,' features the panelists advancing their conversation on major depressive disorder, bipolar depression, and schizophrenia and focusing on how gaps and delays in payer coverage translate into real patient harm, with firsthand examples of how coverage barriers have led to preventable crises and setbacks in psychiatric care.